DRTS
DRTS
IL0011839383
Alpha Tau Medical Ltd.
Loading chart...

Company Profile

Alpha Tau Medical Ltd., a clinical-stage oncology therapeutics company, focuses on the research, development, and commercialization of diffusing alpha-emitters radiation therapy (Alpha DaRT) for the treatment of solid cancer. Its Alpha-DaRT technology is in clinical trials for various forms comprising skin, oral, pancreatic, prostate, lung, liver, and breast cancers; and preclinical clinical studies for mouse tumors and human-derived tumors. The company has a strategic collaboration agreement to develop and commercialize Alpha DaRT for the treatment of prostate cancer. The company is headquartered in Jerusalem, Israel.

Latest News

Related stocks

1952.HK
1952.HK • China
EVEREST MED
29.6 HKD
1.33B USD 1Y -47.1%
KARD
KARD • United States
Kardigan, Inc.
14.67 USD
1.37B USD
2595.HK
2595.HK • China
GENFLEET-B
28.6 HKD
1.4B USD 1Y -21%
2160.T
2160.T • Japan
GNI GROUP LTD
3,200 JPY
1.33B USD 1Y +34.6%
COAG
COAG • United States
Hemab Therapeutics Holdings, In
31.62 USD
1.48B USD
RAPP
RAPP • United States
Rapport Therapeutics, Inc.
30.65 USD
1.47B USD 1Y +10.3%
LBRX
LBRX • United States
LB Pharmaceuticals Inc
37.22 USD
1.2B USD 1Y +130.1%
MAZE
MAZE • United States
Maze Therapeutics, Inc.
27.11 USD
1.51B USD 1Y -9.5%

Key Metrics & Overview

Detailed metrics & financial data of the company

Company Profile
5 Metrics

🛡️ Risk & Structural Analysis

Multi-Factor Risk Model & Market Data

7/7 Very High
5Y Volatility
80.3% p.a.
Max Drawdown (5Y)
-86.9%
Sharpe Ratio (5Y)
0.06
Beta Factor
1.22
Size Class
Small Cap
Notes & Warnings
Single Stock Risk: Investing in an individual stock carries full company and insolvency risk (no fund diversification).
Exemplary balance sheet strength: Very solid ratio of equity to debt.
🔴 Low analyst coverage – higher uncertainty in growth estimates & projections
Structurally High Volatility: Above-average fluctuations persist across 5 to 10 years (80.3% p.a.).
Historical Stress Test: Maximum peak-to-trough drawdown of -86.9% in the extended horizon.
ende